Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor*
暂无分享,去创建一个
K Dane Wittrup | Gerd Ritter | Nathan E Hall | Antony W Burgess | Jennifer R Cochran | Yong-Sung Kim | A. Scott | A. Burgess | J. Cochran | K. Wittrup | F. Walker | E. Nice | L. Old | A. Jungbluth | C. Ward | N. E. Hall | Yong-Sung Kim | T. Johns | T. Adams | M. Olsen | Terrance G Johns | Timothy E Adams | Peter A Hoyne | Mark J Olsen | Julie Rothacker | Edouard C Nice | Francesca Walker | Achim A Jungbluth | Lloyd J Old | Colin W Ward | Andrew M Scott | G. Ritter | J. Rothacker | P. Hoyne
[1] G. Stragliotto,et al. Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. , 1996, European journal of cancer.
[2] P. Humphrey,et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[3] A. Scott,et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. , 2001, Cancer research.
[4] A. Wakeling. Epidermal growth factor receptor tyrosine kinase inhibitors. , 2002, Current opinion in pharmacology.
[5] D. Bigner,et al. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. , 1998, Journal of neurovirology.
[6] C. James,et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.
[7] Careen K. Tang,et al. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. , 2000, Cancer research.
[8] A. Scott,et al. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. , 2001, Cancer research.
[9] M. Sliwkowski,et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.
[10] C. Arteaga,et al. Unliganded Epidermal Growth Factor Receptor Dimerization Induced by Direct Interaction of Quinazolines with the ATP Binding Site* , 1997, The Journal of Biological Chemistry.
[11] Eric T. Boder,et al. Yeast surface display for screening combinatorial polypeptide libraries , 1997, Nature Biotechnology.
[12] Edward S. Kim,et al. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer , 2001, Seminars in oncology.
[13] Monilola A. Olayioye,et al. The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.
[14] A. Scott,et al. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[15] Roy S Herbst,et al. Monoclonal antibodies to target epidermal growth factor receptor–positive tumors , 2002, Cancer.
[16] R. Jorissen,et al. Identification of a determinant of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain. , 2001, Biochemistry.
[17] Hyun-soo Cho,et al. Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether , 2002, Science.
[18] C. James,et al. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[19] Jae-Hoon Kim,et al. Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.
[20] A. Scott,et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[21] P. Humphrey,et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[22] J. Teissié,et al. High Efficiency Transformation of Intact Yeast Cells by Electric Field Pulses , 1990, Bio/Technology.
[23] R. McLendon,et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. , 1995, Cancer research.
[24] S. Ho,et al. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. , 1989, Gene.
[25] N. Senzer. Rationale for a phase III study of erythropoietin as a neurocognitive protectant in patients with lung cancer receiving prophylactic cranial irradiation. , 2002, Seminars in oncology.
[26] E. Rowinsky,et al. The ErbB receptor family: a therapeutic target for cancer. , 2002, Trends in molecular medicine.
[27] K. Ramyar,et al. A mammalian expression vector for expression and purification of secreted proteins for structural studies. , 2000, Protein expression and purification.
[28] Roy S Herbst,et al. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. , 2002, Seminars in oncology.
[29] J. Cochran,et al. Domain-level Antibody Epitope Mapping through Yeast Surface Display of Epidermal Growth Factor Receptor Fragments , 2022 .
[30] C. Arteaga. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. , 2002, Seminars in oncology.
[31] E C Nice,et al. Instrumental biosensors: new perspectives for the analysis of biomolecular interactions. , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.
[32] S. Larson,et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. , 1991, Journal of the National Cancer Institute.
[33] Richard M Caprioli,et al. Characterization of glycosylation sites of the epidermal growth factor receptor. , 2003, Biochemistry.
[34] M. Morrow,et al. Chemoprevention of breast cancer: a model for change. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] S. Decker. Aspects of the metabolism of the epidermal growth factor receptor in A431 human epidermoid carcinoma cells , 1984, Molecular and cellular biology.
[36] Hyun-soo Cho,et al. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. , 2003, Molecular cell.
[37] A. Kaye,et al. Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme. , 1988, Cancer research.
[38] W. Cavenee,et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[39] W. Gullick,et al. Specific targeting of a mutant, activated egf receptor found in glioblastoma using a monoclonal antibody , 1995, International journal of cancer.
[40] R. Nicholson,et al. EGFR and cancer prognosis. , 2001, European journal of cancer.
[41] A. Scott,et al. Novel monoclonal antibody specific for the de2‐7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene , 2002, International journal of cancer.
[42] Edouard C. Nice,et al. Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.
[43] A. Halpern,et al. Cutaneous side‐effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 , 2001, The British journal of dermatology.